| Hazard Information | Back Directory | [Uses]
JMS-17-2 hydrochloride is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. JMS-17-2 hydrochloride impairs metastatic seeding and colonization of breast cancer cells[1]. | [in vivo]
JMS-17-2 (10 mg/kg; aministered i.p.; twice a day for three weeks) causes a dramatic reduction of tumors in both skeleton and visceral organs in SCID mice[1]. | Animal Model: | SCID mice (~25g) with MDA-231 xenograft[1] | | Dosage: | 10 mg/kg | | Administration: | Aministered i.p.; twice a day for three weeks | | Result: | Caused a dramatic reduction of tumors in both skeleton and visceral organs. |
| [storage]
Desiccate at RT | [References]
[1] Shen F, et al. Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells. Mol Cancer Res. 2016 Jun;14(6):518-27. DOI:10.1158/1541-7786.MCR-16-0013 |
|
| Company Name: |
R&D Systems, Inc
|
| Tel: |
18003437475 18003437475 |
| Website: |
www.rndsystems.com |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|